Avisi Technologies Thought Leadership Impact at LSI US ’25
Recap of Avisi CEO’s Participation in Two Impactful Panels at LSI Emerging Medtech Summit
Avisi Technologies returns to the Life Science Intelligence (LSI) stage with CEO Rui Jing Jiang participating in several panel discussions at the 2025 MedTech Summit. The panel discussions involved leadership and design strategies for achieving success within the MedTech industry. Life Science Intelligence has been a trusted name in market intelligence, and their products and services have been a cornerstone of the industry for nearly two decades. Their annual Emerging MedTech Summit is the premier event for the MedTech industry, bringing Investors, Founders, and the brightest minds within the community together.
Panel #1
The first panel, “Staying Sexy Without GenAI or Saas—Building Deceptively Simple but Brilliant Products,” challenged the panelists to consider how they built their companies without these tools and what the future holds. Focusing on an industry crowded with startups incorporating GenAI or Saas, these four executives describe the design and development process to turn ideas into reality.
Panel #2
The second panel, “Building a Winning Board — Hits and Misses,” touches on the value a strong board of directors can bring to a company and the strategies on how to build it. This panel unpacks the key traits to look for when building your board, the common missteps to avoid, and balancing the right amount of expertise and leadership to drive meaningful value to help companies reach their milestones.
About VisiPlate®
The investigational VisiPlate® aqueous shunt is Avisi Technologies’ flagship “minimally invasive bleb surgery” (MIBS) device. Made from non-fibrotic nanotechnology-enabled metamaterials, it works by wicking pent-up aqueous humor from the inside of the eye to a secondary drainage zone via a network of interconnected microchannels, rather than a large tube. The device is engineered to lower IOP while maintaining patient comfort and aesthetics. It is an investigational device and is not yet available for sale.
About Glaucoma
Glaucoma is the leading cause of irreversible blindness worldwide and currently has no cure. In glaucoma patients, excess fluid builds up within the eye, increasing pressure on the optic nerve and leading to permanent vision loss. Glaucoma is a group of diseases, the most common of which are primary open-angle glaucoma (POAG) and angle-closure glaucoma. POAG, the most prevalent form of glaucoma, often has no early warning signs or symptoms. It occurs when the eye’s drainage system (trabecular meshwork) becomes clogged, preventing normal fluid outflow and leading to elevated eye pressure. Without diagnosis and treatment, POAG can cause gradual vision loss over time.
About Avisi Technologies
Avisi Technologies is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company’s portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate® aqueous shunt, a sustained drug delivery platform, and a device to treat mild glaucoma. Avisi Technologies’ VisiPlate device has been recognized as a promising new technology by numerous organizations, including the National Science Foundation, the Glaucoma Research Foundation, SXSW, Johnson & Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others. Avisi has been funded by early-stage venture capital investors, angel investors, and research grants from the National Science Foundation. For more information, visit avisitech.com.
Sources:
Photo Credit: Life Science Intelligence
LSI LinkedIn Panel Announcements
